Corrigendum to “Comparative analysis of novel modified drug delivery systems for improving the oral bioavailability of water-insoluble tadalafil using copovidone, TPGS and hydroxypropyl-β-cyclodextrin” [Biomed. Pharmacother. 186 (2025) 118039] (Biomedicine & Pharmacotherapy (2025) 186, (S0753332225002331), (10.1016/j.biopha.2025.118039))

  • Fakhar ud Din
  • , Dong Shik Kim
  • , Jung Suk Kim
  • , Seunghyun Cheon
  • , Seonghyeon Park
  • , Sanghyun Woo
  • , Mi Ran Woo
  • , Zakir Ali
  • , Jong Oh Kim
  • , Sung Giu Jin
  • , Han Gon Choi

Research output: Contribution to journalComment/debate

Abstract

The authors regret mentioning Klucel under 'Materials' section supplied by Shin Etsu. The statement needs to be replaced as, < “ KlucelTM (HPC; LF, ELF) was obtained from Ashland (Wilmington, Delaware, United States). Hydroxypropylmethylcellulose (2910; 3, 4.5, 6 and 15 cps) (HPMC) and polyvinyl alcohol (PVA) were obtained from Shin-Etsu Co. (Tokyo, Japan)” >. The authors would like to apologise for any inconvenience caused. DOI of original article: < 10.1016/j.biopha.2025.118039>

Original languageEnglish
Article number118127
JournalBiomedicine and Pharmacotherapy
Volume187
DOIs
StatePublished - Jun 2025

Fingerprint

Dive into the research topics of 'Corrigendum to “Comparative analysis of novel modified drug delivery systems for improving the oral bioavailability of water-insoluble tadalafil using copovidone, TPGS and hydroxypropyl-β-cyclodextrin” [Biomed. Pharmacother. 186 (2025) 118039] (Biomedicine & Pharmacotherapy (2025) 186, (S0753332225002331), (10.1016/j.biopha.2025.118039))'. Together they form a unique fingerprint.

Cite this